Skip to content

Duchenne Muscular Dystrophy Video Assessment Registry

Duchenne Muscular Dystrophy Video Assessment Registry

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05712447
Acronym
ARISE
Enrollment
150
Registered
2023-02-03
Start date
2022-09-01
Completion date
2026-01-11
Last updated
2026-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duchenne Muscular Dystrophy

Keywords

Duchenne, DMD, Remote video assessment

Brief summary

ARISE is a prospective and longitudinal clinical study of individuals with Duchenne Muscular Dystrophy (DMD) aimed at creating a database of functional motor abilities in this population to support validation efforts of the Duchenne Video Assessment (DVA).

Detailed description

ARISE is a longitudinal, observational study of individuals with Duchenne muscular dystrophy (DMD). The Duchenne Video Assessment (DVA) is a home-based clinical outcome assessment that measures ease of movement through identification of compensatory movement patterns. The DVA directs caregivers to video record patients doing specific movement activities at home using a secure mobile application. In this study, participants will remotely complete the DVA in addition to existing DMD functional assessments (North Star Ambulatory Assessment (NSAA) and Performance of Upper Limb (PUL 2.0)) to evaluate the longitudinal measurement properties of the DVA.

Interventions

None listed

Sponsors

The Emmes Company, LLC
Lead SponsorINDUSTRY
United States Department of Defense
CollaboratorFED

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* At least 2 years of age at time of consent * Written consent (English only) by adult participant or parent/legal guardian of minor participant * Written assent (English only) if minor participant is at least 7 years of age * Documentation provided for the participant's diagnosis of DMD (i.e., genetic report, clinic note)

Exclusion criteria

Participants will be excluded if they are unable to use a hand to hold a pen, pick up pennies or drive a powerchair.

Design outcomes

Primary

MeasureTime frameDescription
Duchenne Video Assessment (DVA)24 monthsThe DVA is a home-based clinical outcome assessment that measures ease of movement through identification of compensatory movement patterns. The DVA includes 18 standardized movement tasks that are assigned to participants based on functional subgroup. The DVA directs and trains caregivers to video record patients doing specific movement tasks at home using a secure mobile application. DVA videos are scored by DVA-certified physical therapists using validated scorecards with prespecified compensatory movement criteria.

Secondary

MeasureTime frameDescription
North Star Ambulatory Assessment (NSAA)24 monthsThe NSAA is a 17-item tool used to measure functional motor abilities in ambulatory individuals with DMD. Physical therapists with experience administering the NSAA will remotely administer and record the live NSAA sessions via a secure video conference platform. Participants will receive the appropriate standardized testing equipment.
Performance of Upper Limb 2.0 (PUL 2.0)24 monthsThe PUL 2.0 is a 22-item rating scale used to measure upper limb abilities in individuals with DMD. The test includes an entry test item to define starting functional level and 21 test items subdivided into shoulder level, elbow level, and distal level. Physical therapists with experience administering the PUL 2.0 will remotely administer and record the live PUL 2.0 sessions via secure video conference platform. Participants will receive the appropriate standardized testing equipment.
Caregiver Task-Specific Impression of Change24 monthsAt each follow-up assessment timepoint, parents/legal guardians or recording partners will complete an electronic questionnaire to rate their impression of change in the participant's ability to perform each DVA movement task since the prior timepoint.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORMarielle Contesse, PhD

Emmes Endpoint Solutions

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026